Form 4: Repligen CFO Jason K. Garland Reports Stock and Option Awards
SEC Form 4 Filing
Repligen's CFO, Jason K. Garland, reports the acquisition of restricted stock units and stock options, according to a Form 4 filing with the SEC.
Summary
- On February 27, 2024, Jason K. Garland, CFO of Repligen Corporation, was awarded 2,540 restricted stock units (RSUs), each representing a contingent right to receive one share of Repligen's common stock.
- These RSUs vest in equal annual installments over three years, starting on the first anniversary of the grant date.
- Mr. Garland also acquired 2,523 stock options with an exercise price of $192.71.
- These options vest in three equal annual installments starting February 27, 2025.
- Following these transactions, Mr. Garland directly owns 8,043 shares of Repligen common stock and 2,523 stock options.
- The filing was signed by Kimberly Brown, Attorney in Fact, on February 29, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices, which are generally viewed favorably as they align management's interests with shareholders.
Positives
- The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for a CFO in a publicly traded company.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
- Companies like Thermo Fisher Scientific and Danaher also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see the grants as a reflection of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of the transaction: Grant of restricted stock units and stock options to Jason K. Garland. |
| 02/27/2025 | First vesting date for one-third of the stock options. |
| 02/27/2026 | Second vesting date for one-third of the stock options. |
| 02/27/2027 | Third vesting date for one-third of the stock options. |
| 02/27/2034 | Expiration date of the stock options. |
| 02/29/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.